Abstract: Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 ?g selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and/or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.

Abstract: Disclosed are topical skin care compositions and corresponding methods of using those compositions in preventing, retarding, or treating the harmful effects of solar radiation on skin. The compositions comprise 05?-adenosine-diphosphate ribose (ADPR) and a dermatologically acceptable carrier, wherein the compositions are applied topically to the skin prior to, during, or shortly after exposure to the sun. It has been found that 05?-adenosine-diphosphate ribose is unique among many nucleoside derivatives in protecting skin cells from the harmful effects of solar radiation, especially UV radiation.

Abstract: Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas.

Abstract: An apparatus for altering characteristics of a fluid. The apparatus includes a canister having a side wall, a first end wall, and a second end wall defining a chamber therein. A beneficial agent is disposed in the chamber. The end walls define apertures therethrough. The apparatus further includes a tubing portion defining a first end portion constructed for connection to a fluid source and an outlet portion. The tubing portion also defines a canister-receiving portion intermediate the first end portion and the outlet portion. The canister-receiving portion defines a first fluid flow channel fluidly connecting the first end portion and the second outlet portion of said tubing portion. The canister-receiving portion also defines first and second fluid flow orifices therethrough.